MILAN, Italy — Aurigene Pharmaceutical Services Limited, a leading Contract Research, Development and Manufacturing Organization (CRDMO), has won the CPHI Pharma Award 2026 in the True Partnership Excellence category for its Zoliflodacin End-to-End Multiparty Partnership. Presented at the CPHI Celebration in Milan, Italy, the award recognizes excellence in collaboration and the collective expertise required to overcome complex pharmaceutical development and manufacturing challenges.
The achievement reflects the collaborative efforts of Aurigene, Dr. Reddy’s Laboratories (DRL), Innoviva Specialty Therapeutics (IST) and the Global Antibiotic Research & Development Partnership (GARDP), bringing together complementary expertise to address demanding technical and manufacturing requirements.
Commenting on the achievement, Akhil Ravi, CEO of Aurigene Pharmaceutical Services, said, “This award reflects years of deep collaboration with innovator partners and seamless integration across research, manufacturing, and supply chain. We believe that strong partnerships, backed by technical excellence and shared commitment to patients, are essential to advancing innovative medicines. This recognition inspires us to continue strengthening our capabilities and delivering meaningful impact for our partners and the patients they serve.”
The CPHI Pharma Awards celebrate excellence and innovation across the global pharmaceutical industry, bringing together organizations and experts shaping the sector's future. This recognition reinforces the value of an integrated CRDMO model in supporting pharmaceutical programs through critical development and manufacturing milestones.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
